Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 August 2004

Other malignant neoplasms in patients with Gastrointestinal Stromal Tumors (GIST)

Włodzimierz Ruka, Piotr Rutkowski, Zbigniew I. Nowecki, Anna Nasierowska-Guttmejer, Maria Dębiec-Rychter

Med Sci Monit 2004; 10(8): LE13-14 :: ID: 11743


Dear Editor,
Gastrointestinal stromal tumors (GIST) compose a recently defined pathological entity, which due to molecular identification of characteristic mutation in c-KIT membrane receptor gene (detected by CD117 immunostaining) and introduction of first effective molecular targeted anticancer agent – imatinib mesilate – tyrosine kinase inhibitor (e.g. c-KIT) has focused attention of oncologists over the world [1,2]. The results of new epidemiological studies suggest that GIST is the most common abdominal mesenchymal tumor with the frequency of 16–20 cases/1 million/year. However, the clinico-pathological features of GIST are not well described. There are some data regarding the associations between GIST and other malignant tumors. The single cases of coexistence of GIST and the renal cancer, cancer of the gall bladder, gastric cancer and lymphoma of the stomach were described [3]. GIST may also occur as a part of other tumors syndromes. The description of so called Carney’s triad includes the presence in one patient during his life: gastric GIST, paraganglioma and pulmonary chondromas [4]. GIST may also occur in association with neurofibromatosis type 1. The presence of other malignant neoplasms in the past history of GIST patients may be important issue. We analyzed the incidence of other malignant neoplasms in large group of patients with GIST. We performed a single-institution retrospective analysis of 180 consecutive patients (92 men and 88 women, median age 57 years; range: 19–82 yrs) with GIST treated between September 1999 and October 2003. All pathologic diagnoses were confirmed by positive immunostaining for CD117. During clinical examination all patients were interviewed for past history of other malignancies. Among the 180 GIST patients we found 18 patients with a history of other malignant neoplasms (10.0%). Two GIST patients suffered from more than one other malignancy. Most of these 18 GIST patients had gastric localization (72%), median age was 60 years, there were 8 men and 10 women; 5 cases were inoperable/metastatic (and treated with imatinib – 4 of them responded). Two women had a history of breast cancer (moreover one of them also suffered from chronic lymphocytic leukemia), 2 female patients were successfully treated for renal cell carcinoma, 2 men – for planoepithelial lung cancer and other 2 women – for invasive cancer of the uterine cervix. We also observed: 2 cases of gastric cancer, 2 cases of colon cancer, 1 case of gastric carcinoid, 1 case of the endometrial adenocarcinoma, 1 case of the uterine sarcoma and 1 case of seminoma (third neoplasm – primary spindle-cell bone sarcoma was diagnosed in this patient during imatinib treatment due to GIST liver metastases). In 2 patients treated primarily for GIST of the stomach multiple pulmonary chondromas were diagnosed (Carney’s triad). In 4 patients also benign soft tissue tumors (lipomas) were diagnosed. Six cases of non-GIST tumors occurred after diagnosis or simultaneously with GIST. The other metachronous tumors were resected and any patient relapsed. All of these non-GIST tumors were considered sporadic (no family history). Our data are supported by observation of Chacon et al. [5] on smaller cohort of GIST patients, who found also approximately 10% GIST patients with prior history of other solid cancers. A high ratio of other malignancies in GIST patients focused the attention of clinical oncologists on this problem and may imply a common genetic mechanism of their etiology. It is not possible to answer yet if it is the common genetic mechanism or random co-incidence in patients undergone special supervision during follow-up (however, most of these GIST tumors – 15/18 were in high potential of aggressiveness not like the cases found accidentally during the surgery from other indications). Moreover, the fact of this frequent coexistence does not deprive the patient of the possibility of the only effective treatment in unresectable/metastatic GIST – imatinib and it cannot be the exclusion criterion for treatment of recurrent GIST in case of other metachronous malignancy, which had been previously successfully treated.
1. DeMatteo RP: The GIST of targeted cancer therapy: a tumor(gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular
inhibitor (STI 571). Ann Surg Oncol, 2002; 9: 831–39
2. Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer, 2002; 38(Suppl.5): S39–S51
3. Antonini C, Forgiarini O, Chiara A et al: Stromal tumor of the ileum (GIST) at the same time as renal carcinoma. Description of the case and review of the literature. Pathologica, 1998; 90: 160–64
4. Carney JA: Gastric stromal sarcoma, pulmonary chondroma and extra-adrenal paragnaglioma (Carney triad): natural history, adrenocortical component and possible familial occurrence. Mayo Clin Proc, 1999; 74: 543–52
5. Chacon M, Roca E, Barugel M et al: Report of solid cancer in patients with gastrointestinal stromal tumours (GIST) Annual Meeing Proceedings American Society of Clinical Oncology, 2004; Abstract 9065,
page 830

Keywords: Piperazines - pharmacology, Antineoplastic Agents - pharmacology, Benzamides, Gastrointestinal Neoplasms - etiology, Neoplasms - etiology, Piperazines - pharmacology, Proto-Oncogene Proteins c-kit - immunology, Pyrimidines - pharmacology



15 August 2022 : Editorial  

Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide

Nahum Méndez-Sánchez, Ming-Hua Zheng, Takumi Kawaguchi, Shiv K. Sarin
Liver Research Unit, Medica Sur Clinic & Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

DOI: 10.12659/MSM.938080

Med Sci Monit 2022; 28:e938080

In Press

12 Aug 2022 : Clinical Research  

Risk Factors and Pathogen Spectrum in Continuous Ambulatory Peritoneal Dialysis-Associated Peritonitis: A S...

Med Sci Monit In Press; DOI: 10.12659/MSM.937112  

11 Aug 2022 : Meta-Analysis  

Optimal Surgical Treatment Method for Anterior Cruciate Ligament Rupture: Results from a Network Meta-Analysis

Med Sci Monit In Press; DOI: 10.12659/MSM.937118  

10 Aug 2022 : Review article  

Programmed Cell Death in Diabetic Nephropathy: A Review of Apoptosis, Autophagy, and Necroptosis

Med Sci Monit In Press; DOI: 10.12659/MSM.937766  

10 Aug 2022 : Database Analysis  

Use and Effects of Augmentation of Labor with Oxytocin: A Single-Center, Retrospective, Case-Control Study ...

Med Sci Monit In Press; DOI: 10.12659/MSM.937557  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750